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Background: The Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) was designed to monitor in vitro
antimicrobial susceptibility to tigecycline and comparator agents. We present susceptibility data on Gram-negative
organisms collected between 2005 and 2011 from nine United States census regions.
Methods: T.E.S.T. was conducted using standardized CLSI methodologies or FDA-approved breakpoints.
Results: Tigecycline was highly active (MIC90 ≤ 2 mg/L) against Enterobacteriaceae irrespective of species or region
of collection (N = 25011). The isolates were also highly susceptible to the carbapenems when all regional data are
combined, except for ESBL-producing Klebsiella pneumoniae (MIC90 16 mg/L) and Acinetobacter baumannii (MIC90
≥ 32 mg/L). In addition, 883 (30%) of 2900 A. baumannii isolates were classified as multidrug-resistant (MDR): these
MDR organisms were most susceptible to tigecycline (MIC90 2 mg/L) and minocycline (MIC90 8 mg/L) when all
regional data are considered together. Susceptibility patterns also varied widely among the regions.
Conclusions: The findings highlight the importance of monitoring antimicrobial susceptibility patterns and
implementing effective methods to curb increased resistance and also confirm that additional studies to determine
the efficacy of tigecycline in vivo, especially for treating infections with MDR organisms, are warranted.
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Infection with Acinetobacter spp. and some members of
the Enterobacteriaceae present clinicians with consider-
able challenge, especially since resistance to carbapenems
is becoming increasingly prevalent [1,2]. Such infections
result in increased mortality and morbidity, and the in-
creased hospitalization costs continue to put enormous
strain on the healthcare system [3-5]. Against this back-
ground, surveillance studies designed to monitor anti-
microbial resistance of Gram-negative bacteria collected
from regions throughout the USA are essential.
Tigecycline is a novel glycylcycline antimicrobial that
overcomes several common mechanisms used by bacteria
to develop resistance [6]. Confirmation of the effectiveness* Correspondence: gdenys@iuhealth.org
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reproduction in any medium, provided the orof tigecycline against a broad spectrum of microorganisms
resulted in licensing by the US Food and Drug Adminis-
tration (FDA) for the treatment of complicated skin and
skin structure infections (cSSSIs), intra-abdominal infec-
tions (cIAIs), and community-acquired bacterial pneumo-
nia (CAP) [7].
The Tigecycline Evaluation and Surveillance Trial (T.E.
S.T.) is a multi-center study designed to monitor the
in vitro activity of tigecycline and a wide range of other
antimicrobial agents against clinically-important Gram-
positive and Gram-negative pathogens collected globally.
This report focuses on data obtained from Gram-negative
organisms collected in the USA. In a previous report,
Halstead et al. [8] confirmed significant in vitro activity of
tigecycline against A. calcoaceticus-baumannii complex,
Enterobacter spp., Escherichia coli, and Klebsiella pneu-
moniae isolates and highlighted the ability of localtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antimicrobial therapy. This study reports the in vitro
activity of tigecycline against A. baumannii and other
Enterobacteriaceae isolates. In addition, the susceptibil-
ity patterns among nine distinct regions within the
USA are presented and emerging trends in resistance
are evaluated by comparing the results to previous
findings [8].Methods
Isolate collection
Gram-negative isolates were collected between 2005 and
2011 from 173 centers that were divided into nine cen-
sus regions: East North Central, 31; East South Central,
11; Middle Atlantic, 44; Mountain, 7; New England, 7;
Pacific, 11; South Atlantic, 33; West North Central, 16;
West South Central, 13. The states contained in each
census region are shown in Table 1.
The centers submitted clinically-significant (deter-
mined by local criteria) Gram-negative isolates that
were collected consecutively. The organisms included
Acinetobacter spp., E. coli, Enterobacter spp., Serratia
spp., and Klebsiella spp. A single isolate was collected
from each patient and inclusion was independent of
medical history, previous antimicrobial use, sex or age
of the patient.
Organisms were identified using routine methodolo-
gies practiced regularly at each institution. Prior to
eligibility for participation, the medical centers were
evaluated by the central laboratory (IHMA: Laborator-
ies International for Microbiology Studies, a division
of International Health Management Associates, Inc.
[IHMA, Schaumburg, IL, USA]) for adherence to na-
tional guidelines. In addition, IHMA confirmed the
identification of organisms or antimicrobial susceptibility
patterns using RapidOne and/or RapidNF identificationTable 1 Numbers of isolates contributed by census regiona in




A. baumannii 103 72 332 694
E. coli 240 235 813 1477
K. pneumoniae 181 164 590 1174
K. oxytoca 57 50 176 301
S. marcescens 87 61 302 544
Enterobacter spp. 227 192 770 1351
Total 895 774 2983 5541
a Pacific = California, Hawaii, Oregon, and Washington; Mountain = Arizona, Colorad
Minnesota, Missouri, Nebraska, North Dakota, and South Dakota; East North Central
Jersey, New York, and Pennsylvania; New England = Connecticut, Maine, Massachus
Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, and W
Tennessee; West South Central = Arkansas, Louisiana, Oklahoma, and Texas.systems (Remel, Lenexa, KS) when the forwarded results
were uncharacteristic.Susceptibility testing
Minimum inhibitory concentrations (MICs) were deter-
mined using broth microdilution methodology, Sensititre®
plates (TREK Diagnostic Systems, West Sussex, England)
or MicroScan® panels (Siemens, Sacramento, CA, USA).
Susceptibility to amikacin, amoxicillin-clavulanate, ampi-
cillin, carbapenems (imipenem/meropenem), cefepime,
ceftazidime, ceftriaxone, levofloxacin, minocycline, and
piperacillin-tazobactam were interpreted according to the
guidelines published by the Clinical and Laboratory
Standards Institute [9-11]. In addition, susceptibility to
imipenem was evaluated on isolates collected through
2006; meropenem was substituted thereafter due to
imipenem stability issues. MIC values against tigecycline
were evaluated using FDA-approved breakpoints provided
in the package insert [7]. Quality control strains were E.
coli ATCC 25922 and P. aeruginosa ATCC 27853. Results
are presented as MIC90.Extended-spectrum β -lactamase (ESBL) testing
Extended spectrum β-lactamase (ESBL) production by E.
coli or Klebsiella spp. was also confirmed using accepted
methodology [10]. Briefly, discs that contained cefotaxime
(30 μg), cefotaxime/clavulanic acid (30/10 μg), ceftazidime
(30 μg), or ceftazidime/clavulanic acid (30/10 μg) (Oxoid,
Inc., Ogdensburg, NY, USA) were placed onto Mueller-
Hinton agar (Remel, Inc., Lenexa, KS) plates after they
were overlaid with the isolate. Organisms where the com-
bination of cefotaxime and ceftazidine discs yielded a zone
of inhibition larger by >5 mm than the zone of inhibition
for cefotaxime or ceftazidime were considered ESBL-












721 77 562 162 177 2900
1892 226 1248 391 398 6920
1518 170 1096 331 311 5535
279 45 145 49 68 1170
609 67 475 140 136 2421
1500 198 1118 339 370 6065
6519 783 4644 1412 1460 25011
o, New Mexico, Montana, and Utah; West North Central = Iowa, Kansas,
= Indiana, Illinois, Michigan, Ohio, and Wisconsin; Middle Atlantic = New
etts, New Hampshire, and Vermont; South Atlantic = Delaware, District of
est Virginia; East South Central = Alabama, Kentucky, Mississippi, and
Table 2 Antimicrobial susceptibility for Acinetobacter baumannii and multidrug-resistant (MDR) A. baumannii

















N = 103 N = 72 N = 332 N = 694 N = 721 N = 77 N = 562 N = 162 N = 177 N = 2900
Amikacin MIC50 4 4 4 8 4 4 4 4 4 4
MIC90 ≥128 ≥128 ≥128 ≥128 64 8 64 ≥128 ≥128 ≥128
%S 71.8 69.4 80.4 58.8 78.1 100 85.1 69.8 71.2 74.3
Carbapenems MIC50 1 1 1 4 1 1 1 2 1 1
MIC90 16 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32
%S 76.7 69.4 74.7 50.3 70.3 74.0 74.0 66.7 80.2 67.4
Cefepime MIC50 16 8 8 16 16 16 8 32 8 16
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 46.6 55.6 55.7 38.2 42.7 48.1 52.8 40.1 55.9 46.3
Ceftazidime MIC50 16 ≤8 ≤8 ≥64 32 16 16 ≥64 ≤8 32
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 48.5 55.6 52.4 35.6 43.8 45.5 49.6 37.0 57.6 44.9
Ceftriaxone MIC50 32 16 16 64 32 32 32 ≥128 16 32
MIC90 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128
%S 30.1 30.6 35.8 19.3 25.8 22.1 27.0 20.4 31.6 25.9
Levofloxacin MIC50 0.5 0.25 0.25 8 8 4 2 8 1 4
MIC90 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16
%S 55.3 62.5 56.9 33.1 40.5 46.8 51.1 35.8 53.7 44.4
Minocycline MIC50 ≤0.5 ≤0.5 ≤0.5 1 ≤0.5 1 1 2 ≤0.5 ≤0.5
MIC90 4 8 8 8 8 4 8 8 8 8
%S 91.3 80.6 87.3 80.5 88.2 97.4 81.5 68.5 88.7 84.1
Pip-taz MIC50 16 8 4 128 16 8 16 64 16 16
MIC90 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256
%S 53.4 56.9 59.9 36.5 53.8 61.0 54.4 43.8 59.3 50.5
Tigecycline MIC50 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
MIC90 1 1 1 2 2 1 2 1 2 2
%S – – – – – – – – – –
MDR Acinetobacter
baumannii
N = 28 N = 23 N = 72 N = 326 N = 206 N = 13 N = 124 N = 50 N = 41 N = 883
Amikacin MIC50 ≥128 ≥128 64 ≥128 32 4 32 ≥128 64 64
MIC90 ≥128 ≥128 ≥128 ≥128 ≥128 8 ≥128 ≥128 ≥128 ≥128
%S 10.7 8.7 36.1 16.0 42.2 100 40.3 6.0 12.2 27.3
Carbapenems MIC50 16 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32
MIC90 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32 ≥32
%S 21.4 8.7 15.3 4.6 12.1 0.0 1.6 10.0 26.8 8.7
Cefepime MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 32 32 ≥64 32 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 0.0 4.3 4.2 10.4 2.4 0.0 5.6 2.0 2.4 5.9
Ceftazidime MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 3.6 4.3 1.4 9.2 3.4 0.0 4.0 2.0 0.0 5.2
Ceftriaxone MIC50 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128
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Table 2 Antimicrobial susceptibility for Acinetobacter baumannii and multidrug-resistant (MDR) A. baumannii
(Continued)
MIC90 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128
%S 3.6 0.0 0.0 0.9 0.5 0.0 0.8 0.0 0.0 0.7
Levofloxacin MIC50 ≥16 8 8 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16
MIC90 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16
%S 0.0 4.3 2.8 0.9 2.4 0.0 0.0 0.0 0.0 1.2
Minocycline MIC50 1 4 4 2 2 2 4 4 4 2
MIC90 8 8 16 8 16 4 8 8 8 8
%S 82.1 56.5 69.4 77.9 72.3 92.3 65.3 54.0 68.3 72.1
Pip-taz MIC50 ≥256 ≥256 ≥256 ≥256 128 128 ≥256 ≥256 ≥256 ≥256
MIC90 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256 ≥256
%S 3.6 4.3 8.3 3.1 10.7 15.4 3.2 2.0 2.4 5.4
Tigecycline MIC50 1 1 1 1 1 1 1 1 1 1
MIC90 2 1 2 2 2 4 2 2 2 2
%S – – – – – – – – – –
Amoxicillin-clavulanate and ampicillin are not presented in this table as they are inactive against A. baumannii.
% S, % susceptible, pip-taz piperacillin-tazobactam, carbapenems = imipenem/meropenem.
– No CLSI approved interpretive criteria availableData not presented when N < 10 isolates.
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for quality control.
Statistical analyses
The Fisher’s Exact test (SAS, Version 8.2) was used to
assess the relationships between the susceptibility/non-
susceptibility results presented in the current report
compared with previous T.E.S.T. study data. Compari-




A total of 2900 isolates of A. baumannii were evaluated
(Table 2). Regardless of the region, the MIC90 for tige-
cycline was ≤ 2 mg/L (MIC50 0.5 mg/L), but formal con-
clusion regarding susceptibility was not possible because
breakpoint values have not been established. The isolates
were also highly susceptible to minocycline (84.1%).
Carbapenem susceptibility ranged from 50% in East North
Central to 80% in West South Central. In addition, some
susceptibility patterns varied significantly among census
regions. For example, there was dramatic regional vari-
ation in the numbers of isolates susceptible to amikacin in
the East North Central (58.8% susceptible) region com-
pared to the numbers obtained from the New England
(100% susceptible) region.
A total of 883 (30.4%) A. baumannii isolates were
multidrug resistant (MDR, resistant to three or more clas-
ses of antimicrobial agent [β-lactams, aminoglycosides,
carbapenems or fluoroquinolones]) and the frequencies
ranged from 16.9% (13/77) in the New England region to47.0% (326/694) in the East North Central region. Fur-
thermore, MDR isolates were susceptible to minocycline
(MIC50 2 mg/L, MIC90 8 mg/L) in some instances, but
minocycline-nonsusceptible isolates were commonly re-
covered from the East South Central (54% susceptibility)
and Mountain regions (56.5%) (Table 2). In contrast,
MDR A. baumannii appeared universally susceptible to
tigecycline (MIC50 1 mg/L, MIC90 2 mg/L).
Escherichia coli
Non-ESBL-producing E. coli isolates (n = 6643) were
highly susceptible to amikacin, carbapenems, cefepime,
ceftriaxone, and tigecycline (Table 3). In contrast, the or-
ganisms were significantly less susceptible to ampicillin,
and the frequency of resistant organisms varied widely
by region (e.g. susceptibility rates of 41.4% in East South
Central region, 54.1% in the West North Central region).
E. coli isolates that produced ESBL were also relatively
uncommon (277 [4.0%] of 6920 isolates), but the highest
frequency was detected in isolates from the Mountain
region (11.1%, 26/235). In addition, ESBL producers
were highly susceptible to amikacin (MIC50 4 mg/L,
MIC90 16 mg/L, 94.9% susceptible), carbapenems (MIC50 ≤
0.06 mg/L, MIC90 0.25 mg/L, 98.2% susceptible), and
tigecycline (MIC50 0.25 mg/L, MIC90 0.5 mg/L, 100%
susceptible) (Table 4).
Klebsiella pneumoniae and K. oxytoca
Non-ESBL producing K. pneumoniae and K. oxytoca
(Table 3) were highly susceptible (>90%) to cefepime,
carbapenems, amikacin, and tigecycline regardless of
region; susceptibility was only slightly lower for
Table 3 Antimicrobial susceptibility for Enterobacteriaceae

















N = 230 N = 209 N = 801 N = 1411 N = 1811 N = 220 N = 1192 N = 384 N = 385 N = 6643
Amikacin MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 4 8 4 4 4 4 4 8 4 4
%S 99.6 99.0 100 99.5 99.3 99.5 99.0 98.2 99.7 99.4
Amoxi-clav MIC50 4 8 4 8 8 4 4 8 8 8
MIC90 16 32 16 16 16 32 32 32 16 16
%S 77.0 71.8 80.8 75.7 76.1 76.4 75.4 70.1 76.4 76.0
Ampicillin MIC50 4 ≥64 4 32 ≥64 8 ≥64 ≥64 ≥64 32
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 52.6 44.0 54.1 47.4 46.3 51.4 45.4 41.4 43.4 47.2
Carbapenems MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.25 0.25 0.25 0.12 0.25 0.25 0.25 0.25 0.25 0.25
%S 100 99.0 99.6 99.7 99.6 99.1 99.1 97.7 99.7 99.4
Cefepime MIC50 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
MIC90 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
%S 99.1 99.0 99.6 99.1 98.8 99.1 98.5 98.2 99.5 99.0
Ceftriaxone MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.12 1 0.12 0.25 0.25 0.25 0.25 0.5 0.12 0.25
%S 97.0 90.4 96.9 96.7 93.9 93.2 94.3 91.1 96.4 94.9
Levofloxacin MIC50 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
MIC90 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16 ≥16
%S 77.8 76.1 79.7 74.7 72.5 78.6 70.6 72.1 74.0 74.0
Minocycline MIC50 1 1 1 1 1 1 1 1 1 1
MIC90 8 16 8 8 8 8 8 8 8 8
%S 86.1 80.4 89.6 84.5 83.4 83.6 85.2 85.9 86.0 85.0
Pip-taz MIC50 1 1 1 1 1 1 1 1 1 1
MIC90 4 4 4 4 4 4 4 4 4 4
%S 95.2 94.3 97.5 96.7 97.1 96.8 96.1 96.9 97.7 96.7
Tigecycline MIC50 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12
MIC90 0.25 0.25 0.25 0.5 0.5 0.25 0.25 0.25 1 0.5
%S 100 100 99.9 100 99.9 100 100 100 100 100
K. pneumoniae
(ESBL negative)
N = 159 N = 151 N = 575 N = 1061 N = 1250 N = 150 N = 991 N = 320 N = 294 N = 4951
Amikacin MIC50 2 1 1 1 2 1 2 1 1 1
MIC90 2 2 2 2 8 2 2 2 2 2
%S 100 98.7 99.5 99.8 97.2 99.3 98.6 99.1 99.0 98.7
Amoxi-clav MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 8 16 8 8 32 8 16 16 8 16
%S 95.0 88.7 93.6 90.8 82.2 90.0 87.4 89.1 91.2 88.2
Ampicillin MIC50 32 ≥64 32 ≥64 ≥64 ≥64 ≥64 ≥64 32 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 2.5 0.7 1.9 1.2 2.6 4.0 1.7 1.3 1.7 1.9
Carbapenems MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
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Table 3 Antimicrobial susceptibility for Enterobacteriaceae (Continued)
MIC90 0.12 0.5 0.25 0.25 0.5 0.12 0.25 0.12 0.5 0.25
%S 100 97.4 99.5 98.8 92.5 99.3 97.8 99.1 99.7 97.2
Cefepime MIC50 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
MIC90 ≤0.5 ≤0.5 ≤0.5 ≤0.5 4 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
%S 99.4 98.0 99.1 99.4 93.0 99.3 98.2 99.1 99.0 97.4
Ceftriaxone MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.12 0.5 0.25 0.25 8 0.25 0.5 0.25 0.25 0.5
%S 98.7 91.4 96.5 95.4 84.6 94.0 91.7 96.3 97.3 92.2
Levofloxacin MIC50 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06 0.06
MIC90 0.25 0.5 0.5 0.5 ≥16 1 1 1 0.5 1
%S 99.4 93.4 96.3 95.5 86.2 90.7 92.9 94.7 97.3 92.7
Minocycline MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 16 16 8 16 16 8 16 16 8 16
%S 84.9 78.8 85.2 79.5 80.4 85.3 82.0 82.2 83.3 81.6
Pip-taz MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 8 8 8 8 64 4 8 8 8 8
%S 96.9 92.1 97.6 96.0 88.6 95.3 94.6 97.8 96.6 94.1
Tigecycline MIC50 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
MIC90 1 1 1 1 2 1 2 2 2 2
%S 96.2 94.7 95.5 96.4 94.9 97.3 95.9 96.6 96.3 95.8
Klebsiella oxytoca N = 57 N = 50 N = 176 N = 301 N = 279 N = 45 N = 145 N = 49 N = 68 N = 1170
Amikacin MIC50 2 2 2 2 2 1 2 2 1 2
MIC90 4 4 4 4 4 2 4 4 2 4
%S 100 96.0 100 99.7 98.9 100 97.2 100 100 99.1
Amoxi-clav MIC50 2 2 4 2 4 2 2 2 4 2
MIC90 8 32 32 16 32 4 32 8 8 16
%S 93.0 82.0 82.4 88.7 79.6 97.8 84.8 91.8 91.2 85.6
Ampicillin MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 32 ≥64 ≥64 ≥64 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 0.0 2.0 0.6 2.3 0.0 2.2 2.1 0.0 0.0 1.1
Carbapenems MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.12 0.5 0.25 0.25 0.5 0.25 0.25 0.12 0.25 0.25
%S 100 94.0 100 98.7 99.6 100 97.9 98.0 100 99.0
Cefepime MIC50 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
MIC90 ≤0.5 2 2 1 2 ≤0.5 1 ≤0.5 ≤0.5 1
%S 100 96.0 98.9 98.7 98.6 100 96.6 100 100 98.5
Ceftriaxone MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.25 4 4 2 16 0.25 4 0.5 0.5 4
%S 93.0 86.0 83.0 88.7 77.8 97.8 85.5 91.8 92.6 85.6
Levofloxacin MIC50 0.03 0.03 0.06 0.06 0.06 0.03 0.03 0.03 0.06 0.06
MIC90 0.5 0.12 2 0.25 2 0.06 0.5 0.5 0.5 0.5
%S 94.7 96.0 90.9 95.0 93.2 100 93.1 95.9 95.6 94.0
Minocycline MIC50 1 1 1 2 2 1 1 1 1 1
MIC90 2 16 4 8 8 2 4 4 8 8
%S 98.2 86.0 90.3 89.0 87.1 95.6 91.0 95.9 85.3 89.7
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Table 3 Antimicrobial susceptibility for Enterobacteriaceae (Continued)
Pip-taz MIC50 2 1 1 1 1 1 1 1 2 1
MIC90 4 32 ≥256 8 ≥256 2 8 2 8 16
%S 94.7 88.0 86.9 92.4 86.0 97.8 91.7 98.0 94.1 90.4
Tigecycline MIC50 0.25 0.25 0.25 0.25 0.5 0.25 0.25 0.25 0.5 0.25
MIC90 0.5 1 1 1 2 0.5 1 0.5 2 1
%S 100 98.0 99.4 99.0 98.2 100 97.9 100 100 98.9
Serratia marcescens N = 87 N = 61 N = 302 N = 544 N = 609 N = 67 N = 475 N = 140 N = 136 N = 2421
Amikacin MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 8 8 4 4 4 4 4 4 4 4
%S 98.9 98.4 99.3 99.3 99.2 100 98.9 97.9 99.3 99.1
Amoxi-clav MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 2.3 6.6 4.6 1.3 3.3 3.0 3.6 2.1 1.5 2.9
Ampicillin MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 2.3 3.3 3.3 1.3 1.3 3.0 1.1 0.7 0.7 1.6
Carbapenems MIC50 0.12 0.12 0.12 ≤0.06 0.12 0.12 0.12 0.12 ≤0.06 0.12
MIC90 1 1 1 0.5 1 0.12 0.5 0.25 0.5 1
%S 97.7 95.1 95.7 96.7 96.4 100 96.2 96.4 100 96.7
Cefepime MIC50 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
MIC90 ≤0.5 1 1 4 4 ≤0.5 1 ≤0.5 1 2
%S 100 100 98.0 95.4 97.2 100 97.7 97.9 100 97.4
Ceftriaxone MIC50 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
MIC90 2 2 4 32 16 1 4 4 2 8
%S 88.5 86.9 88.7 78.3 77.8 92.5 83.6 86.4 89.7 82.6
Levofloxacin MIC50 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12
MIC90 1 0.5 1 2 2 0.5 1 1 0.5 1
%S 96.6 100 95.0 93.9 93.3 98.5 92.6 96.4 98.5 94.4
Minocycline MIC50 2 4 4 4 4 2 4 4 4 4
MIC90 8 8 8 8 8 8 8 8 8 8
%S 86.2 77.0 75.8 74.1 81.0 88.1 78.9 89.3 73.5 78.7
Pip-taz MIC50 2 1 1 2 1 1 1 1 2 1
MIC90 8 8 4 8 8 4 4 4 4 8
%S 98.9 96.7 97.0 93.6 94.1 98.5 96.2 97.1 97.8 95.5
Tigecycline MIC50 1 1 1 1 1 1 1 1 1 1
MIC90 2 2 2 2 2 2 2 1 2 2
%S 98.9 91.8 97.4 96.5 95.4 97.0 95.4 97.9 91.9 95.9
Enterobacter spp. N = 227 N = 192 N = 770 N = 1351 N = 1500 N = 198 N = 1118 N = 339 N = 370 N = 6065
Amikacin MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 4 4 2 4 4 2 4 2 4 4
%S 100 99.5 99.5 98.7 98.1 99.5 99.2 98.8 98.6 98.9
Amoxi-clav MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 4.8 4.7 7.3 3.3 3.7 2.5 5.5 6.2 5.1 4.7
Ampicillin MIC50 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
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Table 3 Antimicrobial susceptibility for Enterobacteriaceae (Continued)
MIC90 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64 ≥64
%S 2.2 6.3 5.8 2.7 2.9 3.5 2.8 2.9 3.0 3.3
Carbapenems MIC50 ≤0.06 ≤0.06 ≤0.06 ≤0.06 0.12 ≤0.06 ≤0.06 ≤0.06 ≤0.06 ≤0.06
MIC90 0.5 1 0.5 0.5 1 0.5 0.5 0.5 0.5 0.5
%S 100 97.4 98.6 97.9 96.1 99.5 97.9 97.3 97.8 97.6
Cefepime MIC50 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5 ≤0.5
MIC90 2 4 2 4 4 2 4 4 2 4
%S 95.6 96.9 97.0 97.1 95.6 97.5 94.7 94.4 97.6 96.1
Ceftriaxone MIC50 0.25 0.5 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
MIC90 16 64 32 32 64 32 64 64 32 64
%S 79.7 63.5 76.9 72.8 63.8 74.7 71.7 64.3 76.8 70.7
Levofloxacin MIC50 0.03 0.06 0.06 0.06 0.06 0.03 0.06 0.06 0.06 0.06
MIC90 0.25 0.5 0.5 1 4 0.5 4 ≥16 0.5 2
%S 97.8 93.2 93.9 93.0 89.4 98.0 86.8 85.0 93.5 91.0
Minocycline MIC50 2 2 2 4 2 2 2 2 2 2
MIC90 8 16 16 16 16 4 8 8 16 16
%S 87.2 78.1 79.7 77.1 76.3 90.4 80.8 81.1 77.6 79.0
Pip/taz MIC50 2 2 2 2 2 2 2 2 2 2
MIC90 64 128 64 64 64 64 64 64 64 64
%S 85.0 80.2 86.5 84.3 80.9 85.4 82.0 80.2 83.2 83.0
Tigecycline MIC50 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5
MIC90 1 2 1 1 2 1 2 2 2 2
%S 96.0 93.2 96.4 96.3 93.7 98.0 94.8 94.7 97.3 95.3
% S, % susceptible, amoxi-clav amoxicillin-clavulanate, pip-taz piperacillin-tazobactam, carbapenems = imipenem/meropenem.
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There was a marked increase in the MIC90 for several
antimicrobials against Klebsiella spp. collected from the
Middle Atlantic region. In addition, there was a higher
frequency (11%) of K. pneumonia isolates that produced
ESBL (n = 584) compared with the numbers of ESBL-
producing E. coli isolates, and the highest numbers of
ESBL-producing K. pneumonia isolates were recovered
from the Middle Atlantic region (17.7%, 268/1518). The
ESBL-producing isolates were mostly susceptible to
amikacin (77.1%) and carbapenems (74.0%) and were
highly susceptible (92.1%) to tigecycline (Table 4).
Serratia marcescens
S. marcescens isolates were highly susceptible to cefepime
(97.4%), carbapenems (96.7%), tigecycline (95.9%), and
levofloxacin (94.4%) (Table 3). Amikacin (MIC50 2 mg/
L, MIC90 8 mg/L, 99.1% susceptible) and piperacillin-
tazobactam (MIC50 1 mg/L, MIC90 8 mg/L, 95.5%
susceptible) were also active, but susceptibilities to cef-
triaxone and minocycline varied among the census
regions. For example, there were considerably higher
numbers of ceftriaxone-resistant isolates recovered
from the East North Central and Middle Atlantic regionwhen compared with recovery in New England (78.3%
and 77.8% versus 92.5% susceptible). In addition, resist-
ance to minocycline was most prevalent in the West
South Central region (73.5% susceptible).
Enterobacter spp.
Enterobacter spp. were highly susceptible to amikacin
(98.9%), carbapenems (97.6%), and cefepime (96.1%), and
tigecycline (MIC50 0.5 mg/L, MIC90 ≤ 2 mg/L, 95.3%) was
also highly effective (Table 3). In contrast, susceptibility to
ceftriaxone, levofloxacin, and minocycline was more vari-
able, and the differences were most pronounced when
comparing MIC90 values. For example, isolates from the
Pacific region were highly susceptible (79.7%) to ceftriax-
one, while organisms from the Mountain region were con-
siderably more resistant (63.5% susceptibility).
Discussion
Antimicrobial resistance among Gram-negative organisms
continues to be a major concern, especially considering the
potential for the rapid spread of resistance mechanisms
and the limited treatment options that result. In this study,
we examined the activity of β-lactam, aminoglycoside, and
fluoroquinolone antimicrobials against Enterobacteriaceae
Table 4 Antimicrobial susceptibility for ESBL-positive





N = 277 N = 584
Amikacin MIC50 4 16
MIC90 16 32
%S 94.9 77.1
Amoxi-clav MIC50 16 16
MIC90 ≥64 ≥64
%S 29.6 29.1
Ampicillin MIC50 ≥64 ≥64
MIC90 ≥64 ≥64
%S 0.7 0.0
Carbapenems MIC50 ≤0.06 0.12
MIC90 0.25 16
%S 98.2 74.0
Cefepime MIC50 32 16
MIC90 ≥64 ≥64
%S 34.3 48.1
Ceftriaxone MIC50 ≥128 64
MIC90 ≥128 ≥128
%S 2.2 3.1
Levofloxacin MIC50 ≥16 ≥16
MIC90 ≥16 ≥16
%S 5.8 19.9
Minocycline MIC50 4 4
MIC90 ≥32 ≥32
%S 61.0 54.8
Pip-taz MIC50 4 128
MIC90 128 ≥256
%S 79.4 40.1
Tigecycline MIC50 0.25 1
MIC90 0.5 2
%S 100 92.1
% S, % susceptible, amoxi-clav amoxicillin-clavulanate, pip-taz piperacillin-
tazobactam, carbapenems = imipenem/meropenem.
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within the USA. We also examined the susceptibility of
each isolate to tigecycline, a glycylcycline licensed to treat
infections caused by a broad spectrum of microorganisms,
many of which have acquired resistance to treatment
with traditional antimicrobials. In addition, Halstead
et al. [2007] published a comprehensive report of anti-
microbial susceptibilities of Gram-negative isolates col-
lected from the USA during 2004 and 2005 [8] and we
extend the study by determining the antimicrobial sus-
ceptibilities of a more diverse group of isolates thathighlights ongoing nationwide changes in resistance
patterns. It should be noted, however, that we failed to
test each appropriate Gram-negative isolate for suscep-
tibility to imepenem and meropenem, which forced us
to incorporate our findings into the broader category of
carbapenem resistance. However, we are confident this
shortcoming did not prevent valid comparison of our
results with previous findings.
Several other recent studies also determined the sus-
ceptibilities of Gram-negative organisms to multiple
antimicrobial agents [2,12,13], with results similar to this
study. For example, we detected similarly high preva-
lence of sensitivity of K. oxytoca and non-ESBL produ-
cing E. coli to levofloxacin, piperacillin-tazobactam, and
ceftriaxone. In addition, Enterobacter spp., K. oxytoca,
and S. marcescens were highly susceptible to the
carbapenems, while the non-ESBL-producing E. coli and
K. pneumoniae isolates were almost universally suscep-
tible to the carbapenems. However, small numbers of
carbapenem-resistant organisms were recovered from
each genus, which also supports previous findings that
highlight the necessity for continued monitoring for
carbapenem resistance. In addition, A. baumannii isolates
that were highly resistant to multiple other antimicrobial
agents were also highly resistant to the carbapenems
(imipenem/meropenem), a result which has been previ-
ously reported [14]. This is especially disconcerting since
the only option for effective treatment of these highly re-
sistant organisms, especially MDR A. baumannii infec-
tions, may be dependent on salvage agents such as colistin
which introduce a host of additional complications [14,15].
Comparing the susceptibility patterns to previous find-
ings [8] also revealed several important trends. Most
notably, the prevalence of resistant organisms remained
essentially unchanged in the East South Central, Middle
Atlantic, and Pacific regions; the prevalence of organ-
isms that were resistant to levofloxacin also decreased
significantly (p < 0.01). Significant (p < 0.01) increases in
susceptibility were identified in 8 region/organism/anti-
microbial agent combinations between 2004–2005 and
2005–2011, 4 of these occurring in the Middle Atlantic re-
gion. Significant decreases in susceptibility were noted in
26 cases over the same time interval; 12 of these occurred
in East North Central while 8 were noted in South Atlantic.
Notably, in South Atlantic, K. pneumoniae susceptibility to
levofloxacin, amikacin, amoxicillin-clavulanate, cefepime,
minocycline and piperacillin-tazobactam decreased signifi-
cantly. In East North Central, A. baumannii susceptibility
to amikacin, ceftriaxone, levofloxacin, minocycline and
piperacillin-tazobactam reduced significantly while E.
coli susceptibility to amoxicillin-clavulanate, cefepime,
levofloxacin and minocycline decreased significantly.
These findings highlight the importance of local efforts to
monitor changing antimicrobial susceptibility patterns for
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addition, evaluating the infection control practices in
regions where the prevalence of antibiotic resistant organ-
isms has not increased significantly may provide import-
ant insight into effective methods for curbing emerging
resistance in other regions.
Finally, despite the lack of established efficacy standards
for predicting the success of treatment with tigecycline,
our findings confirmed and extended previous observa-
tions of high in vitro activity against Enterobacteriaceae
(E. coli, 100% susceptible; Enterobacter, 98.4% suscep-
tible; ESBL-positive K. pneumoniae, 97.9%) and also A.
baumannii (94.4% susceptible at ≤ 2 mg/L) [16]. There-
fore, additional studies to determine the efficacy of
tigecycline in vivo, especially for treating infections with
MDR organisms, are warranted.
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